1. Home
  2. ASTC vs GNPX Comparison

ASTC vs GNPX Comparison

Compare ASTC & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astrotech Corporation (DE)

ASTC

Astrotech Corporation (DE)

HOLD

Current Price

$3.53

Market Cap

6.1M

Sector

Industrials

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.12

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTC
GNPX
Founded
1984
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
5.0M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
ASTC
GNPX
Price
$3.53
$2.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
38.2K
691.2K
Earning Date
02-13-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,312,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.06
N/A
52 Week Low
$2.47
$1.71
52 Week High
$8.01
$55.00

Technical Indicators

Market Signals
Indicator
ASTC
GNPX
Relative Strength Index (RSI) 49.20 46.01
Support Level $3.30 $1.77
Resistance Level $3.86 $2.75
Average True Range (ATR) 0.18 0.24
MACD -0.02 0.12
Stochastic Oscillator 49.18 45.67

Price Performance

Historical Comparison
ASTC
GNPX

About ASTC Astrotech Corporation (DE)

Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: